Compare TWO & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWO | CDNA |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | 486 | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2007 |
| Metric | TWO | CDNA |
|---|---|---|
| Price | $12.62 | $19.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $12.56 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.3M | 733.8K |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 11.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $409.60 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $8.84 | $10.96 |
| 52 Week High | $14.17 | $23.24 |
| Indicator | TWO | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 72.21 | 47.72 |
| Support Level | $9.55 | $16.63 |
| Resistance Level | $12.67 | $21.20 |
| Average True Range (ATR) | 0.16 | 1.33 |
| MACD | 0.05 | -0.22 |
| Stochastic Oscillator | 93.60 | 38.34 |
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, residential mortgage loans, mortgage servicing rights, and commercial real estate. The majority of its investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. The company derives revenues mainly from its MSR and Agency RMBS portfolio, including servicing fee income, float income, and interest income, as well as mortgage loan origination activities established to support the MSR portfolio. Its investment portfolio is subject to market risks, mainly interest rate, basis, and prepayment risk. The majority of income is generated by available-for-sale securities.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.